CBX2 and acute myeloid leukemia: AP-1 TFs, which act as effectors of receptor tyrosine kinase signaling and growth factor, are activated by the Ras/MAPK pathway [50], suggesting that CBX2 might promote AML through MAPK-associated regulatory sites.